Representative Josh Gottheimer (D-New Jersey) recently sold shares of Johnson & Johnson NYSE: JNJ. In a filing disclosed on April 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Johnson & Johnson stock on March 7th. The trade occurred in the Representative's "MORGAN STANLEY - SELECT UMA ACCOUNT # 1" account.
Representative Josh Gottheimer also recently made the following trade(s):
- Purchased $1,001 - $15,000 in shares of Visa NYSE: V on 3/24/2025.
- Sold $1,001 - $15,000 in shares of Spotify Technology NYSE: SPOT on 3/24/2025.
- Sold $1,001 - $15,000 in shares of Flywire NASDAQ: FLYW on 3/19/2025.
- Sold $1,001 - $15,000 in shares of Disco OTCMKTS: DSCSY on 3/19/2025.
- Sold $1,001 - $15,000 in shares of Snowflake NYSE: SNOW on 3/19/2025.
- Sold $1,001 - $15,000 in shares of Diageo NYSE: DEO on 3/19/2025.
- Sold $1,001 - $15,000 in shares of Shopify NYSE: SHOP on 3/19/2025.
- Sold $1,001 - $15,000 in shares of Perusahaan Perseroan (Persero) PT Telekomunikasi Indonesia Tbk NYSE: TLK on 3/19/2025.
- Sold $1,001 - $15,000 in shares of ServiceNow NYSE: NOW on 3/19/2025.
- Sold $1,001 - $15,000 in shares of Tandem Diabetes Care NASDAQ: TNDM on 3/19/2025.
Johnson & Johnson Stock Up 2.3 %
Shares of JNJ traded up $3.51 during midday trading on Thursday, reaching $157.42. 10,972,370 shares of the company were exchanged, compared to its average volume of 7,960,814. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The company has a market cap of $379.37 billion, a price-to-earnings ratio of 23.67, a P/E/G ratio of 2.56 and a beta of 0.49. The stock has a 50-day moving average price of $159.47 and a 200-day moving average price of $155.06.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.
Johnson & Johnson Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be given a $1.30 dividend. The ex-dividend date is Tuesday, May 27th. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a yield of 3.30%. Johnson & Johnson's dividend payout ratio (DPR) is 74.59%.
Insider Transactions at Johnson & Johnson
In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares of the company's stock, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.16% of the company's stock.
Institutional Trading of Johnson & Johnson
A number of institutional investors and hedge funds have recently made changes to their positions in JNJ. MRP Capital Investments LLC boosted its holdings in shares of Johnson & Johnson by 4.1% during the fourth quarter. MRP Capital Investments LLC now owns 1,640 shares of the company's stock valued at $237,000 after acquiring an additional 65 shares during the period. Syverson Strege & Co raised its holdings in shares of Johnson & Johnson by 4.9% during the fourth quarter. Syverson Strege & Co now owns 1,394 shares of the company's stock valued at $202,000 after buying an additional 65 shares during the last quarter. Werba Rubin Papier Wealth Management grew its holdings in Johnson & Johnson by 3.3% in the 4th quarter. Werba Rubin Papier Wealth Management now owns 2,080 shares of the company's stock worth $301,000 after buying an additional 66 shares in the last quarter. Denali Advisors LLC raised its stake in Johnson & Johnson by 1.3% during the 4th quarter. Denali Advisors LLC now owns 5,128 shares of the company's stock valued at $742,000 after acquiring an additional 67 shares in the last quarter. Finally, Sage Mountain Advisors LLC boosted its position in Johnson & Johnson by 0.5% during the 4th quarter. Sage Mountain Advisors LLC now owns 14,564 shares of the company's stock worth $2,106,000 after acquiring an additional 67 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of equities analysts have weighed in on JNJ shares. Bank of America decreased their price objective on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a research report on Thursday, April 10th. Morgan Stanley raised their price objective on Johnson & Johnson from $164.00 to $169.00 and gave the company an "equal weight" rating in a research note on Wednesday. Stifel Nicolaus cut their target price on Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating on the stock in a research report on Thursday, January 23rd. Sanford C. Bernstein reissued a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday. Finally, Argus raised shares of Johnson & Johnson to a "strong-buy" rating in a report on Friday, January 24th. Nine investment analysts have rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $171.72.
Read Our Latest Report on JNJ
About Representative Gottheimer
Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey's 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2027.
Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey's 5th Congressional District. He declared candidacy for the 2026 election.
Gottheimer is also running for election for Governor of New Jersey. He declared candidacy for the Democratic primary scheduled on June 10, 2025.
Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.
About Johnson & Johnson
(
Get Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Featured Articles
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
